Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program

Alain H. Litwin, Kenneth A. Harris, Shadi Nahvi, Philippe J. Zamor, Irene J. Soloway, Peter L. Tenore, Daniel Kaswan, Marc N. Gourevitch, Julia H. Arnsten

Research output: Contribution to journalArticle

86 Citations (Scopus)

Abstract

Injection drug users constitute 60% of the more than 4 million people in the United States with hepatitis C virus (HCV), including many methadone maintenance patients. Few data exist describing clinical outcomes for patients receiving HCV treatment on-site in methadone maintenance settings. In this retrospective study, we describe clinical outcomes for 73 patients receiving HCV treatment on-site in a methadone maintenance treatment program. Fifty-five percent of patients achieved end-of-treatment response, and 45% achieved sustained viral response. These treatment response rates are nearly equivalent to previously published HCV treatment response rates, despite high prevalences of ongoing drug use (49%), psychiatric comorbidity (67%), and HIV coinfection (32%). These data show that on-site HCV treatment with pegylated interferon and ribavirin is effective in methadone-maintained patients, many of whom are active drug users, psychiatrically ill, or HIV coinfected, and that methadone maintenance treatment programs represent an opportunity to safely treat chronic hepatitis C.

Original languageEnglish (US)
Pages (from-to)32-40
Number of pages9
JournalJournal of Substance Abuse Treatment
Volume37
Issue number1
DOIs
StatePublished - Jul 2009

Fingerprint

Ribavirin
Methadone
Chronic Hepatitis C
Interferons
Hepacivirus
Therapeutics
Drug Users
HIV
Coinfection
Psychiatry
Comorbidity
Retrospective Studies
Injections
Pharmaceutical Preparations

Keywords

  • Chronic hepatitis C
  • HCV
  • Interferon
  • Methadone maintenance
  • Opiate agonist treatment

ASJC Scopus subject areas

  • Psychiatry and Mental health
  • Clinical Psychology
  • Phychiatric Mental Health
  • Medicine (miscellaneous)

Cite this

Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. / Litwin, Alain H.; Harris, Kenneth A.; Nahvi, Shadi; Zamor, Philippe J.; Soloway, Irene J.; Tenore, Peter L.; Kaswan, Daniel; Gourevitch, Marc N.; Arnsten, Julia H.

In: Journal of Substance Abuse Treatment, Vol. 37, No. 1, 07.2009, p. 32-40.

Research output: Contribution to journalArticle

Litwin, Alain H. ; Harris, Kenneth A. ; Nahvi, Shadi ; Zamor, Philippe J. ; Soloway, Irene J. ; Tenore, Peter L. ; Kaswan, Daniel ; Gourevitch, Marc N. ; Arnsten, Julia H. / Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program. In: Journal of Substance Abuse Treatment. 2009 ; Vol. 37, No. 1. pp. 32-40.
@article{7bf87cd496104960a1fd03d1ba661879,
title = "Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program",
abstract = "Injection drug users constitute 60{\%} of the more than 4 million people in the United States with hepatitis C virus (HCV), including many methadone maintenance patients. Few data exist describing clinical outcomes for patients receiving HCV treatment on-site in methadone maintenance settings. In this retrospective study, we describe clinical outcomes for 73 patients receiving HCV treatment on-site in a methadone maintenance treatment program. Fifty-five percent of patients achieved end-of-treatment response, and 45{\%} achieved sustained viral response. These treatment response rates are nearly equivalent to previously published HCV treatment response rates, despite high prevalences of ongoing drug use (49{\%}), psychiatric comorbidity (67{\%}), and HIV coinfection (32{\%}). These data show that on-site HCV treatment with pegylated interferon and ribavirin is effective in methadone-maintained patients, many of whom are active drug users, psychiatrically ill, or HIV coinfected, and that methadone maintenance treatment programs represent an opportunity to safely treat chronic hepatitis C.",
keywords = "Chronic hepatitis C, HCV, Interferon, Methadone maintenance, Opiate agonist treatment",
author = "Litwin, {Alain H.} and Harris, {Kenneth A.} and Shadi Nahvi and Zamor, {Philippe J.} and Soloway, {Irene J.} and Tenore, {Peter L.} and Daniel Kaswan and Gourevitch, {Marc N.} and Arnsten, {Julia H.}",
year = "2009",
month = "7",
doi = "10.1016/j.jsat.2008.09.009",
language = "English (US)",
volume = "37",
pages = "32--40",
journal = "Journal of Substance Abuse Treatment",
issn = "0740-5472",
publisher = "Elsevier Inc.",
number = "1",

}

TY - JOUR

T1 - Successful treatment of chronic hepatitis C with pegylated interferon in combination with ribavirin in a methadone maintenance treatment program

AU - Litwin, Alain H.

AU - Harris, Kenneth A.

AU - Nahvi, Shadi

AU - Zamor, Philippe J.

AU - Soloway, Irene J.

AU - Tenore, Peter L.

AU - Kaswan, Daniel

AU - Gourevitch, Marc N.

AU - Arnsten, Julia H.

PY - 2009/7

Y1 - 2009/7

N2 - Injection drug users constitute 60% of the more than 4 million people in the United States with hepatitis C virus (HCV), including many methadone maintenance patients. Few data exist describing clinical outcomes for patients receiving HCV treatment on-site in methadone maintenance settings. In this retrospective study, we describe clinical outcomes for 73 patients receiving HCV treatment on-site in a methadone maintenance treatment program. Fifty-five percent of patients achieved end-of-treatment response, and 45% achieved sustained viral response. These treatment response rates are nearly equivalent to previously published HCV treatment response rates, despite high prevalences of ongoing drug use (49%), psychiatric comorbidity (67%), and HIV coinfection (32%). These data show that on-site HCV treatment with pegylated interferon and ribavirin is effective in methadone-maintained patients, many of whom are active drug users, psychiatrically ill, or HIV coinfected, and that methadone maintenance treatment programs represent an opportunity to safely treat chronic hepatitis C.

AB - Injection drug users constitute 60% of the more than 4 million people in the United States with hepatitis C virus (HCV), including many methadone maintenance patients. Few data exist describing clinical outcomes for patients receiving HCV treatment on-site in methadone maintenance settings. In this retrospective study, we describe clinical outcomes for 73 patients receiving HCV treatment on-site in a methadone maintenance treatment program. Fifty-five percent of patients achieved end-of-treatment response, and 45% achieved sustained viral response. These treatment response rates are nearly equivalent to previously published HCV treatment response rates, despite high prevalences of ongoing drug use (49%), psychiatric comorbidity (67%), and HIV coinfection (32%). These data show that on-site HCV treatment with pegylated interferon and ribavirin is effective in methadone-maintained patients, many of whom are active drug users, psychiatrically ill, or HIV coinfected, and that methadone maintenance treatment programs represent an opportunity to safely treat chronic hepatitis C.

KW - Chronic hepatitis C

KW - HCV

KW - Interferon

KW - Methadone maintenance

KW - Opiate agonist treatment

UR - http://www.scopus.com/inward/record.url?scp=67349223905&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67349223905&partnerID=8YFLogxK

U2 - 10.1016/j.jsat.2008.09.009

DO - 10.1016/j.jsat.2008.09.009

M3 - Article

VL - 37

SP - 32

EP - 40

JO - Journal of Substance Abuse Treatment

JF - Journal of Substance Abuse Treatment

SN - 0740-5472

IS - 1

ER -